A Cost Utility Analysis of CYP2D6 Pharmacogenetic Guided Dosing Versus Standard Dosing of Risperidone for Treatment of Schizophrenia

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.1271
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy